H.C. Wainwright on March 10, 2026 maintained a Buy rating on Esperion Therapeutics, Inc. (ESPR). This ESPR analyst rating reiteration followed the company’s recent Q4 2025 results and a strategic update tied to the Corstasis acquisition. The firm also set a $16.00 price target, and the stock showed a -0.92% (-$0.02) intraday change on the announcement.
ESPR analyst rating update
On March 10, 2026 H.C. Wainwright reiterated a Buy rating on Esperion Therapeutics (ESPR). The firm cited expectations of continued revenue growth and pipeline progress. The StreetInsider note summarized the call and commentary, and Investing.com recorded the firm’s $16.00 price target for ESPR. StreetInsider
Price target and analyst rationale for ESPR
H.C. Wainwright set a $16.00 ESPR price target and reiterated Buy after the Q4 2025 call. The analyst emphasized sales momentum and the Corstasis acquisition as upside drivers. Investors should weigh the $16 target against the consensus metrics and recent guidance changes. Investing.com
What this ESPR analyst rating means for investors
A maintained Buy signals confidence, not a fresh upgrade. Investors should view the ESPR analyst rating as confirmation of growth expectations. Buy ratings can support higher valuations, but investors must balance optimism against Esperion’s cash flow profile and execution risk.
Historical analyst coverage and context for ESPR
Esperion has drawn mixed coverage, with MarketWatch showing an average target near $6.83 across 7 analysts. H.C. Wainwright is a recurrent voice on ESPR and often drives momentum after conference calls. Historical context shows analyst targets vary widely because Esperion sits in a volatile biotech segment.
Stock performance and link to the ESPR analyst rating
The ESPR analyst rating maintenance coincided with a small intraday decline of -0.92% (-$0.02). Ratings tend to affect short-term flows, but broad moves require multiple firms or new data. Watch volume, relative strength, and upcoming catalysts for clearer price direction.
Meyka AI grade and forward outlook for ESPR
Meyka AI rates ESPR with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade supports the H.C. Wainwright Buy stance, but it is not a guarantee. Meyka AI provides real-time analyst coverage and scenario-driven outlooks for investors.
Final Thoughts
H.C. Wainwright’s March 10, 2026 decision to maintain a Buy on Esperion Therapeutics (ESPR) reinforces existing bullish views. The firm’s $16.00 price target sets a clear upside reference versus current market levels and reflects confidence in revenue growth and the Corstasis acquisition. For investors, this ESPR analyst rating means the stock remains onbuy lists for those comfortable with biotech volatility. Short-term traders may see limited reaction to a maintained rating, but longer-term investors should track execution on guidance, pipeline milestones, and M&A integration. Remember the stock’s market cap is roughly $533,332,480, and consensus targets vary, so use the rating with portfolio-sized risk controls. Meyka AI’s B+ grade summarizes favorable metrics and analyst sentiment, while reminding investors these views are not financial advice.
FAQs
What did H.C. Wainwright say about Esperion on March 10, 2026?
H.C. Wainwright reiterated a Buy rating on Esperion on March 10, 2026 and set a $16.00 price target. The firm cited continued growth expectations after the Q4 2025 results. This is the latest entry in ESPR analyst rating coverage.
How should investors interpret the maintained Buy on ESPR?
A maintained Buy means the analyst still favors Esperion’s prospects but did not increase conviction. Investors should weigh the ESPR analyst rating against valuation, $16.00 target, market cap, and upcoming catalysts before adding exposure.
Does the ESPR analyst rating change imply immediate price movement?
Not necessarily. The March 10, 2026 maintained Buy coincided with a -0.92% intraday move. Maintained ratings often have muted short-term effects unless paired with new data or broader analyst shifts.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)